Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy

Jeff East, Lucas Blanton

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia. We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone. Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy. Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.

Original languageEnglish (US)
Pages (from-to)1081-1083
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Dapsone
Hyperbilirubinemia
Hemolysis
Anti-Retroviral Agents
Pneumocystis carinii
Pneumocystis Pneumonia
Hemolytic Anemia
Therapeutics
HIV
Atazanavir Sulfate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. / East, Jeff; Blanton, Lucas.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 2, 02.2012, p. 1081-1083.

Research output: Contribution to journalArticle

@article{516df14acc5949cd9f26f382a320023d,
title = "Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy",
abstract = "The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia. We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone. Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy. Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.",
author = "Jeff East and Lucas Blanton",
year = "2012",
month = "2",
doi = "10.1128/AAC.05806-11",
language = "English (US)",
volume = "56",
pages = "1081--1083",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy

AU - East, Jeff

AU - Blanton, Lucas

PY - 2012/2

Y1 - 2012/2

N2 - The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia. We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone. Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy. Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.

AB - The antiretroviral agent atazanavir is associated with mild asymptomatic hyperbilirubinemia. We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone. Symptoms and laboratory evidence of hemolysis resolved upon discontinuation of dapsone, enabling successful antiretroviral therapy. Symptomatic hyperbilirubinemia due to hemolytic anemia is a potential adverse event when using the combination of atazanavir and dapsone in the treatment of patients with the human immunodeficiency virus.

UR - http://www.scopus.com/inward/record.url?scp=84856076005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856076005&partnerID=8YFLogxK

U2 - 10.1128/AAC.05806-11

DO - 10.1128/AAC.05806-11

M3 - Article

C2 - 22123706

AN - SCOPUS:84856076005

VL - 56

SP - 1081

EP - 1083

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -